Soft tissue sarcoma in dogs.

What it is

"Soft tissue sarcoma" (STS) is an umbrella term for tumors arising from mesenchymal tissues — fibrous tissue (fibrosarcoma), peripheral nerve sheaths (peripheral nerve sheath tumor), fat (liposarcoma), smooth muscle (leiomyosarcoma), and others. Many of these behave similarly enough that veterinary oncology groups them clinically.

STS tend to present as firm, fixed, slow-to-medium-growing masses under the skin or within muscle. They invade locally and are notorious for sending microscopic 'tentacles' beyond their visible borders — which is why wide surgical margins matter so much.

Signs to watch for

• A firm subcutaneous or intramuscular mass that has been slowly enlarging over weeks to months.
• Lameness or stiffness if the mass involves a limb.
• A previously small lump that suddenly accelerates in growth.

How veterinarians diagnose it

Fine-needle aspiration of an STS often returns 'mesenchymal cells' — suggestive but not definitive. Tru-cut or incisional biopsy gives histologic confirmation and grade (I, II, or III), which is the most important driver of treatment intensity and prognosis.

Staging — chest radiographs and bloodwork for low/mid-grade tumors; advanced imaging (CT/MRI of the primary site, abdominal ultrasound) for high-grade tumors or those in surgically complex locations.

What treatment usually looks like

• Wide surgical excision with 2–3 cm lateral margins and one fascial plane deep — the single most important factor in long-term control.
• Adjuvant radiation when margins are incomplete and re-excision isn't feasible. Highly effective at reducing local recurrence.
• Chemotherapy (typically doxorubicin-based) for high-grade tumors with significant metastatic risk.
• Toceranib (Palladia) is being studied for some STS subtypes as an alternative to chemotherapy.

Prognosis

Grade is the dominant prognostic factor. Low-grade STS removed with clean margins is often cured. High-grade tumors and incomplete excisions face higher recurrence rates and metastatic risk; reported median survival ranges widely depending on grade and treatment.

Tumor location can constrain the surgeon's ability to get wide margins — a small low-grade STS on a leg may be easier to cure than the same tumor on the face or near a joint, even though biology is identical.

Questions to ask your vet

• What grade is the sarcoma?
• Were surgical margins clean? If not, do we need re-excision or radiation?
• What's the local recurrence risk with our current plan?
• Does my dog need chemotherapy, or is local control sufficient?
• How often should we re-image to catch recurrence early?

Where to learn more

Veterinary teaching hospitals at most accredited US vet schools maintain owner-facing fact sheets on common cancers. Peer-reviewed journals — JAVMA, Veterinary and Comparative Oncology, Frontiers in Veterinary Science — are accessible through PubMed. The American College of Veterinary Internal Medicine (ACVIM) and the Veterinary Cancer Society publish consensus statements you can ask your vet to walk you through.

For clinical trials enrolling dogs with this diagnosis, see the SciRouter Vet trial finder — we index AVMA, NCI COTC, and twelve university registries.